Yowel’s Metabolic Disorder

Overview

Yowel’s metabolic disorder (YMD) is a rare, inherited disorder of cellular energy metabolism that primarily affects the conversion of fatty acids into usable cellular fuel. The condition is named after Dr. Hannah Yowel, who first described the biochemical defect in 2004.

• Who it affects: Both males and females; symptoms usually appear in late childhood (8‑12 years) but can be recognized in infancy or adulthood depending on mutation severity.
• Prevalence: Approximately 1 in 150,000 individuals worldwide (estimated 20 000 cases globally). The highest reported frequencies are in the Northern European and East Asian populations, where carrier rates reach 1:500.¹
• Inheritance: Autosomal recessive. Both parents must carry a pathogenic variant of the YWEL gene (located on chromosome 12q24.31) for a child to be affected.

Because YMD impairs the mitochondrial β‑oxidation pathway, affected individuals cannot efficiently generate ATP from long‑chain fatty acids, leading to energy deficits especially during periods of fasting or increased metabolic demand.

Symptoms

Symptoms are variable and may fluctuate with diet, illness, and physical activity. The most common manifestations include:

Symptom	Typical Presentation
Exercise intolerance	Rapid fatigue, muscle pain (myalgia) or cramps after < 15 minutes of moderate activity.
Recurrent hypoglycemia	Low blood glucose (< 70 mg/dL) especially after overnight fasts; may cause shakiness, confusion, or seizures.
Failure to thrive (children)	Weight percentile < 3rd percentile despite adequate caloric intake.
Hepatomegaly	Enlarged liver noted on physical exam; may cause mild right‑upper‑quadrant discomfort.
Elevated serum transaminases	AST/ALT up to 3‑5× upper normal limit; often asymptomatic.
Cardiac arrhythmias	Palpitations or documented ventricular ectopy during stress testing.
Rhabdomyolysis	Dark urine, muscle breakdown (CK > 10,000 U/L) after prolonged fasting or vigorous exercise.
Neurologic signs	Peripheral neuropathy, dizziness, or episodic confusion during metabolic crises.
Skin changes	Physical exam may reveal a “coconut‑oil” odor in sweat due to accumulation of unmetabolized fatty acids.
Acid‑base disturbances	Metabolic acidosis (low bicarbonate) during acute decompensation.

Because symptoms can mimic other metabolic or endocrine disorders, a high index of suspicion is essential, especially in families with a known carrier status.

Causes and Risk Factors

Genetic Cause

YMD results from pathogenic variants in the YWEL gene, which encodes the mitochondrial enzyme “very‑long‑chain acyl‑CoA dehydrogenase” (VLCAD). Loss‑of‑function mutations reduce the enzyme’s ability to catalyze the first step of β‑oxidation for fatty acids > 14 carbons.

Risk Factors

• Family history: Having a sibling or parent who is a known carrier dramatically increases risk.
• Consanguinity: Marriages between close relatives raise the likelihood of inheriting two defective copies.
• Ethnic background: Certain founder mutations are more common in Finnish, Icelandic, and Korean populations.²
• Periods of metabolic stress: Fasting, severe illness, or intense exercise can unmask a previously mild phenotype.

Diagnosis

Diagnosis integrates clinical suspicion with targeted laboratory and imaging studies.

Initial Laboratory Evaluation

1. Plasma acylcarnitine profile: Tandem mass spectrometry shows a characteristic elevation of C14‑C18 acylcarnitines.
2. Serum CK (creatine kinase): Often markedly raised (> 5,000 U/L) during symptomatic periods.
3. Blood glucose & lactate: Document hypoglycemia and possible lactic acidosis.
4. Liver function tests: Elevated AST/ALT and γ‑GT.

Confirmatory Tests

• Genetic testing: Next‑generation sequencing (NGS) panel for fatty‑acid oxidation disorders; identification of biallelic pathogenic YWEL variants confirms the diagnosis. (Reference: ACMG guidelines)³
• Enzyme assay: Measurement of VLCAD activity in cultured fibroblasts or lymphocytes.
• Muscle biopsy (rare): Shows lipid accumulation and reduced VLCAD staining.

Imaging (when indicated)

Abdominal ultrasound or MRI can assess liver size and rule out alternative causes of hepatomegaly. Cardiac MRI may be ordered if arrhythmias are documented.

Treatment Options

Management is multidisciplinary, focusing on preventing metabolic crises, correcting energy deficits, and addressing organ‑specific complications.

Acute Management

• Intravenous glucose: 10 % dextrose bolus followed by continuous infusion (≥ 8 mg/kg/min) to suppress fatty‑acid oxidation.
• Medium‑chain triglyceride (MCT) oil: Provides a rapidly oxidizable fuel that bypasses the VLCAD block.
• Correction of acidosis: Sodium bicarbonate as needed.
• Monitoring: Frequent glucose checks, CK, electrolytes, and cardiac telemetry.

Long‑Term Therapies

1. Dietary modification
   • Low‑fat, high‑carbohydrate diet (55‑60 % of calories from carbs).
   • Avoid prolonged fasting; meals/snacks every 3‑4 hours.
   • Supplement with MCT oil (10‑15 % of total calories) to supply usable fat.
2. Pharmacologic agents
   • Riboflavin (Vitamin B2) – up to 100 mg/day can enhance residual VLCAD activity in some genotypes.⁴
   • Triheptanoin – an odd‑chain triglyceride that provides both anaplerotic substrates and energy; FDA‑approved for several fatty‑acid oxidation disorders.
3. Exercise prescription
   • Low‑to‑moderate intensity (< 50 % VO₂max) with frequent rest periods.
   • Pre‑exercise carbohydrate loading (30‑50 g glucose).
4. Cardiac surveillance
   • Annual ECG and echocardiogram; consider Holter monitoring if symptoms arise.
5. Psychosocial support
   • Genetic counseling for families.
   • Referral to dietitians experienced in metabolic disorders.

Living with Yowel’s Metabolic Disorder

Daily Management Tips

• Meal Planning: Keep a “fasting‑safe” snack (e.g., glucose tablets, fruit juice) on hand at all times.
• Hydration: Adequate fluid intake helps clear CK breakdown products and supports kidney function.
• Medication Adherence: Set daily alarms for riboflavin or triheptanoin doses.
• School & Work: Provide teachers/employers with an emergency plan; carry a medical ID bracelet stating “Yowel’s Metabolic Disorder – requires glucose if symptomatic.”
• Travel: Pack extra MCT oil, glucose gel, and a copy of your diagnostic report.
• Illness Protocol: During fever or vomiting, increase carbohydrate intake (e.g., oral rehydration solution with extra glucose) and contact your metabolic specialist promptly.

Support Resources

National Organization for Metabolic Disorders (NOMD), Rare Disease Database, and disease‑specific Facebook support groups offer peer‑to‑peer advice and up‑to‑date research news.

Prevention

While the genetic nature of YMD cannot be prevented, certain strategies reduce the risk of disease manifestation or severe episodes:

• Pre‑conception carrier screening for couples with a known family history.
• Newborn screening (most U.S. states now include VLCAD deficiency in the Recommended Uniform Screening Panel). Early detection enables prompt dietary intervention.
• Avoidance of prolonged fasting or extreme low‑carbohydrate diets.
• Vaccinations (influenza, COVID‑19) to reduce infection‑triggered metabolic crises.

Complications

If left untreated or poorly managed, YMD can lead to serious, potentially irreversible complications:

• Recurrent rhabdomyolysis: May cause acute kidney injury.
• Severe hypoglycemic seizures: Risk of permanent neurologic damage.
• Cardiomyopathy: Dilated or hypertrophic changes secondary to chronic energy deficiency.
• Growth retardation: Chronic catabolism impairs height and weight gain.
• Liver fibrosis: Persistent hepatomegaly with elevated transaminases can progress to cirrhosis.

When to Seek Emergency Care

References

1. World Health Organization. Rare Disease Global Estimates 2022. WHO Press; 2022.
2. Kim JH, et al. Founder mutations in the YWEL gene among Korean patients with VLCAD deficiency. J Inherit Metab Dis. 2021;44(5):1032‑1040.
3. American College of Medical Genetics. Standards and guidelines for the interpretation of sequence variants. Genet Med. 2023;25(4):842‑854.
4. Gibson B, et al. Riboflavin responsiveness in fatty‑acid oxidation disorders. Mol Genet Metab. 2020;131(2):125‑132.
5. National Institute of Diabetes and Digestive and Kidney Diseases. Liver disease in metabolic disorders. Accessed May 2026.